Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478335 · ClinicalTrials.gov registry record · NA
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00478335 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 4 participants.
The verdict
NCT00478335, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).
Interventions
- DRUG sildenafil
- DRUG indomethacin
- DRUG calcitonin
- DRUG hydrochlorothiazide/amiloride
- DRUG Placebo for sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00478335
The ClinicalTrials.gov registry entry for NCT00478335 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which sildenafil is the first listed.
NCT00478335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00478335 about?
NCT00478335 is a clinical study titled "Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus". The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).
What is the current status of trial NCT00478335?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2007-05. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00478335?
The interventions under investigation include: sildenafil (DRUG), indomethacin (DRUG), calcitonin (DRUG), hydrochlorothiazide/amiloride (DRUG), Placebo for sildenafil (DRUG).
Who is sponsoring clinical trial NCT00478335?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.